Quick Answer
Contineum Therapeutics, Inc. reported Stockholders Equity of $260.99 million for fiscal year 2025.
Contineum Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $260.99M | +31.8% |
| 2024 | $198.07M | +391.5% |
| 2023 | -$67.94M | +27.1% |
| 2022 | -$93.21M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $180.47M | -14.2% | +5.3% |
| June 30, 2025 | $171.39M | -21.2% | -7.2% |
| March 31, 2025 | $184.77M | +344.3% | -6.7% |
| December 31, 2024 | $198.07M | +391.5% | -5.8% |
| September 30, 2024 | $210.23M | +443.8% | -3.3% |
| June 30, 2024 | $217.50M | +492.4% | +387.6% |
| March 31, 2024 | -$75.63M | +22.4% | -11.3% |
| December 31, 2023 | -$67.94M | +27.1% | -11.1% |
- Contineum Therapeutics, Inc. showed an increase of +31.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Contineum Therapeutics, Inc.’s stockholders equity has grown by 380.0% (from -$93.21 million to $260.99 million).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: